In the pharmaceutical business, companies hoping to jump on the profit bandwagon of their competitors often release products that have no significant clinical difference to the market leaders. Makers of these “biosimilars” have long argued that their products should be allowed to carry the same generic or non-proprietary names as the name brand leaders. However, many of the major drug franchisors have fought tooth and nail against this practice, claiming territorial rights. Caught in the middle of the billion-dollar onomastic fight has been the US government. Recently, however, the FDA proposed a solution. The generic drug system would be augmented with a random set of four letters. Learn more about the proposed naming rules.
